Rationale, background, and design of the randomized angiotensin receptor antagonist—Angiotensin-converting enzyme inhibitor study (RAAS)
- 1 November 1996
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 78 (10) , 1129-1131
- https://doi.org/10.1016/s0002-9149(96)90065-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Bradykinin-Induced Vasodilation Is Impaired at the Atherosclerotic Site but Is Preserved at the Spastic Site of Human Coronary Arteries In VivoCirculation, 1995
- Characterization of Angiotensin II Receptor Type 2 during Differentiation and Apoptosis of Rat Ovarian Cultured Granulosa CellsBiochemical and Biophysical Research Communications, 1995
- Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries.Journal of Clinical Investigation, 1993
- Effects of Vesnarinone on Morbidity and Mortality in Patients with Heart FailureNew England Journal of Medicine, 1993
- Angiotensin-Converting Enzyme Inhibition Does Not Suppress Plasma Angiotensin II Increase During Exercise in HumansJournal of Cardiovascular Pharmacology, 1993
- Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendanAmerican Heart Journal, 1992
- Endothelial function in chronic congestive heart failureThe American Journal of Cardiology, 1992
- Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart FailureNew England Journal of Medicine, 1991
- Cardioprotective potential of angiotensin converting enzyme inhibitorsJournal Of Hypertension, 1991
- Angiotensin II-forming pathways in normal and failing human hearts.Circulation Research, 1990